Burson-Marsteller Founder Harold Burson Passes Away at Age 98
Harold Burson, once a 14-cents-per-column-inch stringer for a Memphis newspaper, who reported the Nuremberg Trial for the Army radio network in Europe and whose one-man consultancy became by 1983 the world’s largest public relations firm, died on January 10, 2020. He was 98.
Burson played a leading role in transforming the practice of public relations from a cottage industry to a global business that engaged thousands of employees. He stepped down as Chief Executive Officer of Burson-Marsteller in 1988 but continued in an active capacity for more than a quarter century and came to work nearly every day well into his 90s.
In 1999, a survey by PRWeek, a leading public relations industry trade publication, named Burson as “the century’s most influential PR figure.” This recognition reflected his role as counselor to and confidant of corporate chief executive officers, government leaders and heads of public sector institutions.
His PRWeek citation read:
“The architect of the largest public relations agency in the world today (1999), Burson-Marsteller Chairman Harold Burson’s contribution is immense in many other ways besides. He started practicing the concept of integrated marketing decades before the term was even invented. He brought PR into the advertising business at Young & Rubicam as an equal (it’s arguably never been achieved again). His development of training programs set the benchmark that other agencies have only recently caught up with. He has personally sponsored and supported programs, industry bodies, universities and charities to improve the profession. His mentoring of talent has spawned a whole wave of ex-Burson PR agency start-ups. He created a unique Burson culture that still unites former employees. And, last but not least, his personal counsel has enlightened the thinking of boardrooms at many Fortune 100 companies and across the globe.”
He was a strong proponent of the corporation’s role in society as a social entity, insisting that the mission of a corporation was to deliver a good product at a fair price, treat its employees fairly in terms of compensation and retirement, deal fairly with suppliers, support essential community activities in areas where it operated, and reward its stockholders with a fair return on their investment. But he warned that the principal objective of the corporation was to make a profit that enabled it to fund its responsibilities as a social entity.
Born February 15, 1921, in Memphis, Tennessee, the son of emigrants from Leeds, Yorkshire, England, he started school in the third grade and graduated from high school at age 15. He enrolled at the University of Mississippi (Ole Miss) knowing that his campus correspondent stringer job for the Memphis Commercial Appeal would cover his college tuition and expenses. Six months after graduation, he accepted a public relations position at a large engineering and architectural firm when, as he said, “they doubled my salary from $25 to $50 per week and gave me the use of a car.”
Burson enlisted in the United States Army in 1943 and became part of an engineer combat group in Europe. In 1945, he was transferred to the news staff of the American Forces Network a month before the war ended in Europe.
Later in 1945, he was assigned to report on the Nuremberg Trial and was the only reporter to obtain an interview during the trial with Associate Justice Robert H. Jackson, the chief American prosecutor. Although Justice Jackson had vowed not to grant interviews, Burson argued that his audience, the American GIs who fought the war, were entitled to hear firsthand from the chief American prosecutor. Only 24-years-old when the Nuremberg Trial began, Burson was believed to have been the last living reporter who covered the historic trial.
Following his discharge from the Army in 1946, Burson opened a public relations firm in New York in “a tiny nook in a client’s office” next to the desk of a part-time executive assistant. Never having heard the word “differentiation” used in a competitive sense, he described his firm as specializing in business-to-business clients. The firm he worked for before his Army service was in that category and he quickly learned that few business-to-business companies employed public relations consultants.
In 1952, Burson’s firm had a staff of five when a friend at The New York Times, responding to a query from the owner of a Chicago advertising agency, recommended Burson for a Pittsburgh-based project. Through this opportunity, he came to meet William A. (Bill) Marsteller, with whom his name was linked by a hyphen for 65 years. The Burson firm was hired for the project – to publicize the purchase by Rockwell Manufacturing Company of the first helicopter to be used for executive travel. Rockwell subsequently became a full-fledged client.
Shortly thereafter, Marsteller introduced Burson to the chief executive officer of another client, Clark Equipment Company, which led to still more business. The affiliation with Marsteller worked so well that Burson proposed establishing a new company jointly owned by the two parties. It took the name Burson-Marsteller and opened March 2, 1953 with offices in New York and Chicago and offered “integrated communications services” to business-to-business clients, believed to be the first to do so.
In speeches and articles, Burson has cited two “defining moments” that accounted for the company’s rapid growth. The first was the creation of the European Common Market in the late 1950s. Burson’s firm was the second to establish an office in Europe – in Geneva, Switzerland in early 1961 – and announced its intention to become a global operation over the next quarter century. Though still a speck on the public relations spectrum in the U.S., Burson-Marsteller became known as “the other international public relations firm.” During the 1960s, its annual revenues surged tenfold, from $410,000 to $4.4 million.
The firm’s second defining moment was its selection in 1970 by General Motors (GM) to be its sole public relations counsel, a response to allegations that GM hired private investigators to follow the self-appointed public watchdog, Ralph Nader, after his scathing book questioning the safety of GM’s highly touted Chevrolet Corvair. After GM’s CEO was called to testify before a Congressional committee, the company, on instructions from its board of directors, hired an outside public relations firm to consult with management. Competing against the two largest U.S. firms, Burson-Marsteller was chosen for the assignment, which continued for more than a decade.
During the 1970s, the firm’s revenues increased from $5.2 million to $28.3 million. It added about a dozen new offices in Europe, including London, Paris, Brussels and Frankfurt, and in Asia, in Hong Kong, Tokyo and Singapore. Its clients included both American multinationals and local businesses.
In 1979, Burson engineered the merger of Burson-Marsteller and Marsteller Advertising with the global advertising giant Young & Rubicam, becoming a member of its seven-person executive committee. At the time of the merger, Burson-Marsteller had revenues of $28.3 million and 16 offices. Four years later, when Burson-Marsteller became the world’s largest public relations firm, it had revenues of $63.8 million and 30 offices, including branches in Latin America, Australia and the Middle East.
One of the firm’s specialties was crisis management, ranging from the major Tylenol recalls in 1982 and 1985, which were often referred to as models for corporate management in times of crisis, to the celebrated introduction of “New Coke” and the reintroduction of Coca-Cola Classic in 1985, an undertaking in which Burson himself was a prime participant. After the “New Coke” debacle and the re-introduction of Coca-Cola Classic, he summarized the exercise as “[w]e got a hole-in-one after the ball hit the tree.” The firm also represented Union Carbide in the aftermath of the discharge of toxic chemicals at its plant in Bhopal, India; Pan Am Airways after the Lockerbie (Scotland) crash; and Dow Corning following the U.S. Food and Drug Administration’s decision to ban silicone breast implants. Burson-Marsteller also had a long-time active role in representing the Olympic Games and its corporate sponsors.
Burson received numerous awards from public relations organizations including Hall of Fame designations by the Public Relations Society of America, the Arthur W. Page Society, PRWeek, PR News, the Institute of Public Relations, the Alan Campbell Johnson Award (England), as well as numerous citations by colleges and universities in the United States, Europe and China. He was awarded an honorary degree by Boston University in 1988, and a chair in public relations was established in his name in 1995. He is also in the Hall of Fame at his alma mater, Ole Miss, and shares a place in the Humes High School Hall of Fame in Memphis with Elvis Presley.
He was active in numerous public service organizations, principally the John F. Kennedy Center for the Performing Arts. As a board member of Kennedy Center Productions, he negotiated Japan’s $3 million bicentennial gift in 1976 to construct the Terrace Theater. He also was instrumental in establishing the Kennedy Center Corporate Fund in 1977.
Another of his interests was economic education. He was chairman of the Council on Economic Education in the early 1990s and was an active member of the Economic Club of New York since 1979, including serving as chairman of the organization’s centennial dinner in 2007. In conjunction with the dinner, he proposed the creation of a Centennial Society composed of members who contribute at least $10,000 to the establishment of a club endowment fund.
He was a Presidential appointee to the Commission of Fine Arts in Washington and was a member during the deliberations that led to building the Vietnam War Memorial and the redevelopment of Pennsylvania Avenue in the 1980s. He also chaired the Public Relations Advisory Committee of the U.S. Information Agency during the second Reagan administration and under President George H.W. Bush.
In more recent years, he was a member of the board of trustees of the Museum of the American Revolution, which is the first museum that relates the entire history of the American Revolution. He was also a member of the Eisenhower Memorial Commission’s Advisory Committee.
Although never engaged in partisan politics, he served as public relations advisor to President Ronald Reagan after he left the White House. He did so on the basis that his services were offered pro bono.
In 2017, at the age of 96, he published his memoir, THE BUSINESS OF PERSUASION: Harold Burson on Public Relations (RosettaBooks).
Burson was married to Bette Foster Burson for one month short of 63 years. He is survived by two sons, Scott F. Burson (Wendy Liebow Burson) of Lexington, Massachusetts and Mark Burson (Ellen Jones Burson) of Westlake Village, Calif., and five grandchildren: Allison Burson, Esther Burson, Wynn F. Burson (Steven Cateron), Holly Burson and Kelly Burson.
Donations may be made to the Boston University College of Communication.
BCW (Burson Cohn & Wolfe), one of the world’s largest full-service global communications agencies, is in the business of moving people on behalf of clients. Founded by the merger of Burson-Marsteller and Cohn & Wolfe, BCW delivers digitally and data-driven creative content and integrated communications programs grounded in earned media and scaled across all channels for clients in the B2B, consumer, corporate, crisis management, CSR, healthcare, public affairs and technology sectors. BCW is a part of WPP (NYSE: WPP), a creative transformation company. For more information, visit www.bcw-global.com.
Business: (212) 601-3205
Mobile: (646) 506-5871
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom